Invitae (NVTA) Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last twelve months. There are currently 3 sell ratings and 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "strong sell" NVTA shares.
View NVTA analyst ratings or view top-rated stocks.

5 brokerages have issued 12 month price objectives for Invitae's stock. Their NVTA share price forecasts range from $1.00 to $3.00. On average, they predict the company's share price to reach $2.08 in the next year. This suggests a possible upside of 231.2% from the stock's current price.
View analysts price targets for NVTA or view top-rated stocks among Wall Street analysts.

Invitae's stock was trading at $1.86 at the beginning of the year. Since then, NVTA shares have decreased by 66.3% and is now trading at $0.6266.
View the best growth stocks for 2023 here.

Invitae saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 39,310,000 shares, a decline of 32.9% from the August 15th total of 58,580,000 shares. Based on an average daily volume of 9,660,000 shares, the short-interest ratio is presently 4.1 days.
View Invitae's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our NVTA earnings forecast.

Invitae Co. (NYSE:NVTA) released its quarterly earnings results on Tuesday, August, 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.37) by $0.07. The medical research company earned $120.53 million during the quarter, compared to analyst estimates of $121.19 million. Invitae had a negative net margin of 161.92% and a negative trailing twelve-month return on equity of 6,100.71%.

ETFs with the largest weight of Invitae (NYSE:NVTA) stock in their portfolio include WisdomTree BioRevolution Fund (WDNA), iShares Genomics Immunology and Healthcare ETF (IDNA), Global X Telemedicine & Digital Health ETF (EDOC), Global X Genomics & Biotechnology ETF (GNOM) and ARK Genomic Revolution ETF (ARKG).ARK Innovation ETF (ARKK).

Invitae issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $480.00 million-$500.00 million, compared to the consensus revenue estimate of $497.62 million.

59 employees have rated Invitae Chief Executive Officer Sean George on Glassdoor.com. Sean George has an approval rating of 87% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Block (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), Salesforce (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

(NVTA) raised $76 million in an initial public offering on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Invitae's stock is owned by a number of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (12.38%), BlackRock Inc. (7.99%), Sumitomo Mitsui Trust Holdings Inc. (6.49%), State Street Corp (2.84%), Geode Capital Management LLC (1.80%) and Northern Trust Corp (0.82%). Insiders that own company stock include Artur Bergman, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert F Werner, Robert L Nussbaum, Robert L Nussbaum, Sean E George, Sean E George, Shelly D Guyer, Thomas Brida and Yafei Wen.
View institutional ownership trends.

Shares of NVTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVTA stock can currently be purchased for approximately $0.63.

Invitae (NYSE:NVTA) has a market capitalization of $167.31 million and generates $516.30 million in revenue each year. The medical research company earns $-3,106,290,000.00 in net income (profit) each year or ($3.23) on an earnings per share basis.

The company employs 1,700 workers across the globe.

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The official website for the company is www.invitae.com. The medical research company can be reached via phone at (628) 213-3369 or via email at ir@invitae.com.